Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Redsense Medical AB announces today that a new distributor agreement has been concluded with the Ontario-based company CardioMed Supplies Inc. The agreement concerns the distribution of Redsense's system and products across the territiories of Canada and Bermuda, where almost 25,000 patients receive hemodialysis treatment on a regular basis. The current rate of home hemodialysis in the region is approximately 5 percent.
"CardioMed/Nipro Canada is very pleased to bring our renal patients across Canada the Redsense blood leak detection device. Supporting renal patients with a safety quality initiative with Redsense will bring a level of security that renal patients have requested" says Raphael Dubé, President at CardioMed Supplies Inc.
The well-reputed CardioMed Supplies Inc., recently acquired by the Nipro Group, has been a leading distributor and manufacturer of medical devices in Canada since 1978. It offers a complete range of products, with a particular focus on fail-safe devices.
"Today's announcement stems from a wider initiative to open up new markets, alongside our main market in the United States, in view of the upcoming launch of the Redsense Clamp. Canada is one of the most interesting in this regard. We have had close ties to the country for a long time through our long-standing cooperation with Toronto University Hospital, in relation to the Redsense Clamp development; in CardioMed, we now gain a great strategic distribution partner that share our values," says Patrik Byhmer, CEO of Redsense Medical AB.
About Redsense's products
The Redsense Alarm is an established patient safety device that uses fiber-optic technology and light to monitor for blood leakage occurring during hemodialysis treatment. The Redsense Clamp, evaluated in cooperation with Toronto University Hospital, is an accessory to the Redsense Alarm. It connects to the alarm unit via Bluetooth and clamps the bloodline when the alarm goes off, prompting the blood pump to shut down immediately. The Clamp is about to move into clinical validation during the fall at various locations around the world prior to its launch to the market.
This disclosure contains information that Redsense is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on Monday 16 August 2021.